(Q45942814)

English

Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.

scientific article published in August 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/17577218

Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/17577218

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

6

object named as

George Wilding

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

object named as

Mitchell Gross

7

0 references

Dror Michaelson

object named as

Dror Michaelson

4

0 references

9

object named as

Eric J Small

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/17577218

author name string

Jonathan E Rosenberg

1

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/17577218

Vivian K Weinberg

2

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/17577218

W Kevin Kelly

3

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/17577218

Maha H Hussain

5

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/17577218

Douglass Hutcheon

8

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/17577218

language of work or name

0 references

publication date

1 August 2007

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/17577218

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/17577218

110

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/17577218

3

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/17577218

556-563

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/17577218

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22811

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22811

7 January 2021

based on heuristic

inferred from DOI database lookup

Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22811

7 January 2021

based on heuristic

inferred from DOI database lookup

Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22811

7 January 2021

based on heuristic

inferred from DOI database lookup

Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22811

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22811

7 January 2021

based on heuristic

inferred from DOI database lookup

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22811

7 January 2021

based on heuristic

inferred from DOI database lookup

2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22811

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22811

7 January 2021

based on heuristic

inferred from DOI database lookup

Asymptotically Efficient Rank Invariant Test Procedures

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22811

7 January 2021

based on heuristic

inferred from DOI database lookup

A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22811

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.22811

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/17577218

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/17577218

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45942814&oldid=2186406882"